COMP <GO>
SPRO vs JNJ // OPERATING MARGIN
Spero Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SPRO 6
— JNJ 5
▲ OPERATING MARGIN LEADER: SPRO
LAST: $1.06 (-4.50%) • MKT CAP: $64.6M
operating-margins
50.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
operating-margins
34.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPRO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.60% | 25.50% | +1.10 | SPRO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.1x | 18.5x | -13.40 | SPRO | /valuation <GO> |
| Free Cash Flow Yield | -19.53% | 2.97% | -22.50 | JNJ | /fcf-yield <GO> |
| Operating Margin ACTIVE | 50.20% | 34.70% | +15.50 | SPRO | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | SPRO | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | SPRO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.2 | 62.1 | -20.91 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | 23.0x | -16.70 | SPRO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $64.6M | $662.49B | -$662.43B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPRO REV | JNJ REV | SPRO GROSS % | JNJ GROSS % | SPRO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.6M | $94.19B | — | 67.9% | -$12.6M | $19.70B |
| FY 2024 | $371.0K | $88.82B | — | 69.1% | -$23.4M | $19.84B |
| FY 2023 | $933.0K | $85.16B | — | — | -$33.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRO // BETA —
JNJ // BETA 1.08